Objective. We investigated whether opioid use, duration of use, and cumulative dose are associated with an increased risk of Alzheimer's disease (AD).
Introduction
Older persons use opioids frequently, and some studies report increasing prevalence with advancing age [1] . Opioid use has been increasing in Nordic countries [1] [2] [3] [4] although opioid use has been less frequent in Finland than in Norway and Denmark [2] . A Norwegian study found that strong opioid use almost doubled from 2005 to 2010 among the oldest age group (76-to 80-year-olds) when studying persons age 41 to 80 years [4] . Jensen-Dahm et al. [1] reported that 28% of community-dwelling persons with dementia and 17% of those without dementia used opioids in 2010, and the prevalence steadily increased from 65-to 69-year-olds until the oldest age group of those age 95 years or older.
Opioid use is associated with cognitive effects, such as sedation [5] and an increased risk of delirium and longer duration of delirium [6] . Although these cognitive effects of opioids are reversible, delirium is associated with an increased risk of dementia [7] and the safety of longterm opioid use has not been properly investigated [8] . For these reasons, concerns have been raised about whether long-term opioid use is a risk factor for dementia [8, 9] . A previous study found that opioid use was not associated with an increased risk of dementia, except with the highest cumulative doses (adjusted hazard ratio [HR] ¼ 1.29, 95% confidence interval [CI] ¼ 1.02-1.62) [9] . These results raised the question of whether the association between heavy use and risk of dementia reflects actual risk increase of either long-term opioid use or chronic pain, or residual confounding. As sample size in that study was limited to about 800 individuals developing dementia during the follow-up, we aimed to study this issue with our large, nationwide cohort including all persons diagnosed with Alzheimer's disease in Finland. Our objective was to investigate the risk of Alzheimer's disease (AD) associated with opioid use, duration of use, and cumulative use in a nested casecontrol study.
Methods

Study Population and Data Sources
The Medication use and Alzheimer's disease (MEDALZ) cohort comprises all community-dwelling Finnish persons diagnosed with AD during 2005 to 2011 (N ¼ 70,718) [7] . In order to conduct a nationwide nested case-control study, up to four age-, gender-, and region of residence-matched control persons without AD (N ¼ 282,862) were identified for each case at the date of AD diagnoses. The mean age of cases and controls was 80 years at the index date, and 65% were women. Data for this study were extracted from Finnish nationwide health care registers, including the Special Reimbursement Register , Prescription Register (1995-2012), Hospital Discharge Register , and the censuses maintained by Statistics Finland (since 1970). Each resident is assigned a unique social security number that was utilized in data linkage, which was conducted by the Social Insurance Institution of Finland (SII).
Identification of Cases
Cases were identified from the Special Reimbursement Register as having been granted reimbursement for antidementia drugs [10] . To be granted AD reimbursement, predefined criteria must be fulfilled, a statement describing the findings must have been sent to SII, and special reimbursement is granted only if the criteria are fulfilled. The criteria for AD reimbursement include symptoms consistent with AD, a decrease in social capacity over a period of three or more months, a computed tomography/magnetic resonance imaging scan, and possible alternative diagnoses excluded, and the diagnosis is confirmed by a neurologist or geriatrician. AD diagnosis is based on NINCS-ADRDA [11] and DSM-IV [12] criteria for AD. According to diagnostic protocol, computed tomography and magnetic resonance imaging have to be performed to confirm that the changes in the brain are consistent with AD diagnosis.
Identification of Controls
Control persons were identified from the SII register, which includes all residents of Finland. Controls were matched on the date of AD diagnosis, which is referred to as the index date. Control persons were chosen from community-dwelling residents without AD, and they could not have special reimbursement for AD or acetylcholinesterase inhibitor or memantine purchases (N06D) before or within 12 months after the matching date.
Exposure to Opioids
Opioid use was obtained from the National Prescription Register according to Anatomical Therapeutic Chemical (ATC) classification code N02A, excluding codeine combinations (N02AA59) [13] as they were not consistently reimbursed throughout the exposure assessment period. The Prescription Register covers all reimbursed drug purchases for all Finnish residents. Cough syrups including codeine (some also available over the counter [OTC]) were not reimbursed during the exposure assessment period. No other opioid including products used in outpatient care was identified as utilized by the study cohort.
Opioid use was derived since 1995 until three years before the index date (AD diagnosis/matching date). The lag window of three years was utilized to avoid reverse causality (AD or its prodromal symptoms affecting opioid use). Duration of use was modeled with the PRE2DUP modeling method [14] . The method is based on mathematical modeling of personal drug purchasing behavior. Duration of use is modeled from individual purchase histories and by taking into account variation in purchase events, caused by stockpiling of drugs and periods in hospital care when drugs are provided by the care unit and not recorded in the Prescription Register.
Stockpiling was identified based on peaks in daily dose when there was a very short refill time between two purchases (for example, only a few days), followed by a long refill time until the next purchase when stock was used. Each drug substance was modeled separately, and then "any opioid" use periods were constructed by combining overlapping use periods. Thus, during "any opioid use," a person may have used more than one opioid concomitantly or changed from one drug to another if there was no break in drug availability.
Cumulative opioid amounts were calculated according to equivalency ratio to morphine by Svendsen et al. [15] and by drug form (i.e., oral, parenteral, sublingual, and transdermal forms taken into account when defining equivalency rating). These were transformed to total standardized daily doses (TSDs) [9] corresponding to 30 mg of oral morphine and categorized as 0-10, 11-30, 31-90, and >90 TSDs. For example, 60 TSDs means that a person used a cumulative opioid amount corresponding to 30 milligrams of morphine for 60 days. Further, TSDs/d dosages were calculated for each time window by dividing TSD by the cumulative duration of opioid use during the exposure assessment period. TSDs per day were categorized into quartiles and compared with never use of opioids. For subanalysis on the risk associated with specific opioid substances, morphine, hydromorphone, and pethidine were excluded due to low (<100 users) numbers of users.
Covariates
The following diseases were derived from the Special Reimbursement and Hospital Discharge register and used for adjustments: cardiovascular disease (hypertension, coronary artery disease, chronic heart failure, and/ or arrhythmia), diabetes, rheumatoid arthritis, benzodiazepine and related drug use (ATC codes N05BA, N05CD, N05CF), antipsychotic use (N05A, excluding lithium), number of drugs, history of cancer, hospitaltreated depression, stroke, and substance abuse. These were measured at the beginning of the three-year lag window (number of drugs, all other covariates ever before that). Sensitivity analyses were conducted with a five-year lag and without any lag window.
Statistical Analyses
The association between opioid use and AD was assessed with conditional logistic regression due to matched design. Multivariate models were adjusted for cardiovascular disease, diabetes, hospital-treated depression, benzodiazepine and related drug use, antipsychotic use, stroke, number of drugs, history of cancer, rheumatoid arthritis, and substance abuse. Any opioid use, cumulative duration of use, and cumulative dose in TSDs were analyzed. Opioid substances used by the study cohort were also analyzed separately to observe whether specific drugs were associated with risk of AD. These analyses were adjusted for use of other opioid substances during the exposure assessment period (in addition to other covariates included in all multivariate models). Odds ratios are presented with 95% confidence intervals. Statistical analyses were performed with SAS v. 9.4. All data were de-identified before submission to the research team, and therefore ethics committee approval was not required according to Finnish legislation.
Results
Most of the comorbidities were more common among persons with AD compared with persons without AD ( Table 1) . Cardiovascular disease, diabetes, history of hospital-treated depression, stroke, substance abuse, number of drugs used at the baseline, and BZDR and antipsychotic use were more common among persons with AD whereas there was no difference in rheumatoid arthritis and cancer. Persons who had used opioids during the observation period were older than those who had not used opioids, both among persons with and without AD (Supplementary Table S1 ). They also were more likely to be female and to have comorbid conditions.
Cases had used opioids (17.3%) somewhat more often than controls (16.6%) ( (Table 3 ). The only exception to this was the lowest TSD/d category with a five-year lag window (OR ¼ 1.08, 95% CI ¼ 1.04-1.13).
Tramadol was the most frequently used opioid drug (Table 4) . Multiple opioid drugs were used by 1.9% of persons with AD and 1.7% of persons without AD during the exposure assessment period. No specific opioid drug was associated with an increased risk of AD after adjusting for covariates.
Discussion
We did not find an association between opioid use, longer duration, or higher cumulative dose and the risk of AD. Our null findings are consistent with the conclusions of Dublin et al. [9] , who stated that there is no convincing evidence for opioids being associated with dementia. Although an increased risk of dementia among those with the highest cumulative use was observed in that paper, the authors suggested that this may be due to residual confounding and does not represent convincing evidence of a causal relationship. The lack of dose-response relationship with duration of use, cumulative dose, and dose per day are supportive of a nonexisting risk of permanent cognitive impacts of opioid use. Cognitive effects such as sedation and delirium have been associated with acute opioid use [5, 6] , but it is possible that these effects are reversible and do not lead to development of Alzheimer's disease.
The association of opioid use with AD pathogenesis is unknown, although previous studies indicate that the cholinergic and opioid systems interact with each other [16, 17] . The role of opioids as modulators of cholinergic systems seems to be complicated as they have both unfavorable and beneficial effects on cholinergic neurotransmission [16] . Postmortem studies on the brains of opioid abusers suggest neuropathological changes similar to AD [18, 19] . Opioid neurotoxicity may result from inhibition of cell growth and induction of neuron apoptosis [19] . In addition, the dysfunction of the opioid system may be involved in the production of amyloid-b and hyperphosphorylation of tau, which in turn contribute to the pathogenesis of AD [20] . On the other hand, opioids have shown an inhibitory effect on acetylcholinesterase, and they have been examined as structural scaffolds for novel AD therapeutics [16] . Opioids may also inhibit microglial activation that is associated with AD pathogenesis [19] . The inconsistent effects of opioids on cholinergic systems might be one reason why the long-term effect of opioids on AD seems to be neutral in the current study.
However, it is also possible that those who had used the greatest amounts of opioids had died due to other causes (such as cancer) before reaching the advanced age when Alzheimer's disease is most commonly diagnosed, although this is an unlikely explanation because the cases and controls were matched by age. In addition, opioid use patterns and traditions for long-term prescribing may differ between countries, and it is possible that the association can only be found in even higher doses than investigated in our study. It is also possible that some long-term users developed some other cognitive effects than actual dementia as we did not have data on mild cognitive impairment. Other types of studies should assess the safety of long-term opioid use in terms of cognition. It should be noted, though, that Dublin et al. [9] did not find an association between cumulative opioid use and cognitive decline as measured with the Cognitive Abilities Screening Instrument.
Strengths of our study include nationwide data on a large cohort of community-dwelling persons diagnosed with Alzheimer's disease. We had a long exposure assessment period for opioid use in this cohort, starting from at least 10 years before the diagnoses, depending on the year of diagnoses. With the long exposure assessment period and three-year lag window, we were able to reduce the possibility of reverse causality, that is, that prodromal symptoms or the ongoing diagnostic process of AD would have had impact on opioid use. The results were also analyzed without a time window and with a five-year time window, in addition to the main analyses with a three-year window. All analyses were adjusted for multiple comorbidities and medications.
The limitations of this study were related to the registers utilized. Codeine was excluded from analyses as it was not consistently reimbursed during the exposure assessment period and our register data are restricted to reimbursed drugs only. However, it is unlikely that the exclusion of codeine had a large impact on our results as a similar risk increase would be evident with other opioids if opioid use truly were a risk factor for AD. In addition, it is unlikely that codeine use was differentially distributed between cases and controls. The adjusted models included covariates that were restricted to hospital-based diagnoses only and thus likely underestimate depression and substance abuse. We investigated only the association between opioid use and AD and cannot conclude anything on whether opioid use could be associated with some other form of dementia, such as vascular dementia. Persons with mixed forms of dementia were included in this study if the symptoms were considered to be mainly caused by AD in the diagnosis statement. Further studies should be conducted in terms of effects on other dementia types. In addition, as it is possible that higher doses than used in our study population may be associated with dementia risk, further studies should be conducted in populations exposed to high opioid doses.
In conclusion, we did not find evidence that opioid use, longer cumulative duration of use, or high cumulative dose are associated with risk of Alzheimer's disease. However, due to complex interactions between cholinergic and opioid systems, the possibility of potential adverse cognitive effects associated with opioid use cannot be excluded. More studies are needed to further examine this matter. 
